|
Metastatic Renal Cell Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
VEGFR1 rs9582036 AA/AC carriers and rs9554320 CC/AC carriers had more favorable overall survival (OS) in patients with mRCC treated with sunitinib (<i>n</i> = 3), but not in progression-free survival (PFS).
|
28978162 |
2017 |
|
Metastatic Renal Cell Cancer
|
|
0.030 |
GeneticVariation
|
BEFREE |
VEGFR1 rs9582036 and rs9554320 were previously reported the association with sunitinib progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
|
27901483 |
2017 |
|
Metastatic Renal Cell Cancer
|
|
0.030 |
GeneticVariation
|
BEFREE |
VEGFR1 rs9582036 AA/AC carriers and rs9554320 CC/AC carriers had more favorable overall survival (OS) in patients with mRCC treated with sunitinib (<i>n</i> = 3), but not in progression-free survival (PFS).
|
28978162 |
2017 |
|
Metastatic Renal Cell Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
VEGFR1 rs9582036 and rs9554320 were previously reported the association with sunitinib progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
|
27901483 |
2017 |
|
Metastatic Renal Cell Cancer
|
|
0.030 |
GeneticVariation
|
BEFREE |
Ninety-one patients were included.We found that mRCC patients with the CC-variant in rs9582036 in VEGFR1 have a poorer response rate (RR) (0% vs. 46%, p = 0.028), a poorer PFS (10 vs. 18 months, p = 0.033 on univariate and 0.06 on multivariate analysis) and a poorer OS (14 vs. 31 months, p = 0.019 on univariate and 0.008 on multivariate analysis) compared to patients with the AC- and AA-genotypes. mRCC patients with the AA-variant in rs9554320 in VEGFR1 have a poorer PFS (12 vs. 21 months, p = 0.0066 on univariate and 0.005 on multivariate analysis) and a poorer OS (22 vs. 34 months, p = 0.019 on univariate and 0.067 on multivariate analysis) compared to patients with the AC- and CC-genotypes.Interpretation. mRCC patients with the CC-genotype in VEGFR1 SNP rs9582036 have a poorer response rate, PFS and OS when treated with sunitinib.
|
23421954 |
2014 |
|
Metastatic Renal Cell Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Ninety-one patients were included.We found that mRCC patients with the CC-variant in rs9582036 in VEGFR1 have a poorer response rate (RR) (0% vs. 46%, p = 0.028), a poorer PFS (10 vs. 18 months, p = 0.033 on univariate and 0.06 on multivariate analysis) and a poorer OS (14 vs. 31 months, p = 0.019 on univariate and 0.008 on multivariate analysis) compared to patients with the AC- and AA-genotypes. mRCC patients with the AA-variant in rs9554320 in VEGFR1 have a poorer PFS (12 vs. 21 months, p = 0.0066 on univariate and 0.005 on multivariate analysis) and a poorer OS (22 vs. 34 months, p = 0.019 on univariate and 0.067 on multivariate analysis) compared to patients with the AC- and CC-genotypes.Interpretation. mRCC patients with the CC-genotype in VEGFR1 SNP rs9582036 have a poorer response rate, PFS and OS when treated with sunitinib.
|
23421954 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
|
27417418 |
2016 |
|
Endometriosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
The associations between the presence of endometriosis and SNPs in PLGF (rs2268614), HIF-1α (rs11549465), and VEGFR1 (rs9582036) genes lost statistical significance after multiple testing.
|
26773192 |
2016 |
|
Age related macular degeneration
|
|
0.010 |
GeneticVariation
|
BEFREE |
The SNPs rs9554322, rs9582036 and rs9943922 were correlated with AMD.
|
26914796 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The functional FLT1 variant rs9582036 is a prognostic determinant of recurrence in stage I-III NSCLC.
|
26134224 |
2015 |
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
These findings are in agreement with the association of rs9582036 and outcome observed in bevacizumab treated pancreatic cancer patients.
|
23421954 |
2014 |
|
Malignant neoplasm of pancreas
|
|
0.010 |
GeneticVariation
|
BEFREE |
These findings are in agreement with the association of rs9582036 and outcome observed in bevacizumab treated pancreatic cancer patients.
|
23421954 |
2014 |